What is the share price of Venus Remedies Ltd (VENUSREM) today?
The share price of VENUSREM as on 5th December 2025 is ₹745.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Venus Remedies Ltd (VENUSREM) share?
The past returns of Venus Remedies Ltd (VENUSREM) share are- Past 1 week: 5.89%
- Past 1 month: 75.02%
- Past 3 months: 62.20%
- Past 6 months: 71.04%
- Past 1 year: 130.56%
- Past 3 years: 281.88%
- Past 5 years: 458.72%
What are the peers or stocks similar to Venus Remedies Ltd (VENUSREM)?
The peers or stocks similar to Venus Remedies Ltd (VENUSREM) include:What is the market cap of Venus Remedies Ltd (VENUSREM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venus Remedies Ltd (VENUSREM) is ₹995.91 Cr as of 5th December 2025.What is the 52 week high and low of Venus Remedies Ltd (VENUSREM) share?
The 52-week high of Venus Remedies Ltd (VENUSREM) is ₹799.80 and the 52-week low is ₹270.25.What is the PE and PB ratio of Venus Remedies Ltd (VENUSREM) stock?
The P/E (price-to-earnings) ratio of Venus Remedies Ltd (VENUSREM) is 21.98. The P/B (price-to-book) ratio is 1.78.Which sector does Venus Remedies Ltd (VENUSREM) belong to?
Venus Remedies Ltd (VENUSREM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Venus Remedies Ltd (VENUSREM) shares?
You can directly buy Venus Remedies Ltd (VENUSREM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Venus Remedies Ltd
VENUSREM Share Price
745.052.50% (-19.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VENUSREM Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VENUSREM Performance & Key Metrics
VENUSREM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 14.16 | 1.78 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
VENUSREM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VENUSREM Company Profile
Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
VENUSREM Forecast
VENUSREM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VENUSREM
VENUSREM
Income
Balance Sheet
Cash Flow
Annual Normal View
VENUSREM Income Statement
VENUSREM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 402.31 | 374.66 | 327.98 | 375.99 | 600.36 | 608.49 | 565.83 | 613.03 | 678.76 | 725.58 | ||||||||||
Raw Materials | 223.58 | 204.84 | 189.67 | 168.45 | 347.94 | 383.50 | 322.95 | 357.35 | 373.81 | 608.06 | ||||||||||
| Power & Fuel Cost | 4.14 | 4.29 | 4.86 | 4.73 | 4.58 | 4.71 | 5.52 | 6.35 | 6.36 | |||||||||||
| Employee Cost | 34.27 | 39.31 | 42.10 | 46.02 | 46.02 | 52.33 | 57.05 | 66.95 | 75.46 | |||||||||||
| Selling & Administrative Expenses | 78.30 | 79.41 | 54.52 | 67.15 | 95.99 | 85.54 | 92.49 | 100.77 | 105.64 | |||||||||||
| Operating & Other expenses | 9.03 | 5.09 | 7.17 | 52.33 | 8.98 | 11.98 | 17.47 | 10.43 | 23.09 | |||||||||||
EBITDA | 52.99 | 41.72 | 29.66 | 37.31 | 96.85 | 70.43 | 70.35 | 71.18 | 94.40 | 117.52 | ||||||||||
| Depreciation/Amortization | 40.26 | 33.83 | 33.98 | 32.01 | 35.28 | 33.53 | 32.30 | 26.44 | 22.51 | 22.47 | ||||||||||
| PBIT | 12.73 | 7.89 | -4.32 | 5.30 | 61.57 | 36.90 | 38.05 | 44.74 | 71.89 | 95.05 | ||||||||||
| Interest & Other Items | 34.37 | 35.43 | 25.41 | 13.34 | 13.02 | 0.48 | 0.12 | 0.09 | 0.07 | 0.04 | ||||||||||
| PBT | -21.64 | -27.54 | -29.73 | -8.04 | 48.55 | 36.42 | 37.93 | 44.65 | 71.82 | 95.01 | ||||||||||
| Taxes & Other Items | -4.56 | 3.16 | -1.15 | 1.96 | -13.21 | -4.32 | 11.36 | 16.15 | 26.51 | 24.68 | ||||||||||
| Net Income | -17.08 | -30.70 | -28.58 | -10.00 | 61.76 | 40.74 | 26.57 | 28.50 | 45.31 | 70.33 | ||||||||||
| EPS | -14.36 | -24.87 | -23.16 | -8.10 | 50.04 | 31.69 | 19.88 | 21.32 | 33.90 | 52.61 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
VENUSREM Company Updates
VENUSREM Stock Peers
VENUSREM Past Performance & Peer Comparison
VENUSREM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Venus Remedies Ltd | 21.98 | 1.78 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
VENUSREM Stock Price Comparison
Compare VENUSREM with any stock or ETFCompare VENUSREM with any stock or ETF
VENUSREM
VENUSREM Holdings
VENUSREM Shareholdings
VENUSREM Promoter Holdings Trend
VENUSREM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VENUSREM Institutional Holdings Trend
VENUSREM Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.93%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VENUSREM Shareholding Pattern
VENUSREM Shareholding Pattern
VENUSREM Shareholding History
VENUSREM Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VENUSREM stock
smallcases containing VENUSREM stock
Looks like this stock is not in any smallcase yet.
VENUSREM Events
VENUSREM Events
VENUSREM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VENUSREM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VENUSREM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VENUSREM has not given any dividends in last 5 years
VENUSREM Upcoming Dividends
VENUSREM Upcoming Dividends
No upcoming dividends are available
VENUSREM Past Dividends
VENUSREM Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2013
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2013
Cash Dividend
Ex DateEx DateSep 20, 2012
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 20, 2012
Cash Dividend
Ex DateEx DateSep 22, 2011
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 22, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2010
VENUSREM Stock News & Opinions
VENUSREM Stock News & Opinions
Articles & Videos
Spotlight
Venus Remedies Ltd leads gainers in 'B' group
Zuari Industries Ltd, Vipul Ltd, Orient Ceratech Ltd and Urban Company Ltd are among the other gainers in the BSE's 'B' group today, 11 November 2025.Venus Remedies Ltd spiked 14.69% to Rs 538 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 27045 shares were traded on the counter so far as against the average daily volumes of 1651 shares in the past one month. Zuari Industries Ltd soared 12.02% to Rs 343. The stock was the second biggest gainer in 'B' group. On the BSE, 66349 shares were traded on the counter so far as against the average daily volumes of 13731 shares in the past one month. Vipul Ltd surged 9.89% to Rs 9.33. The stock was the third biggest gainer in 'B' group. On the BSE, 30899 shares were traded on the counter so far as against the average daily volumes of 64353 shares in the past one month. Orient Ceratech Ltd added 9.71% to Rs 39.09. The stock was the fourth biggest gainer in 'B' group. On the BSE, 54188 shares were traded on the counter so far as against the average daily volumes of 5194 shares in the past one month. Urban Company Ltd jumped 8.11% to Rs 143.95. The stock was the fifth biggest gainer in 'B' group. On the BSE, 11.44 lakh shares were traded on the counter so far as against the average daily volumes of 6.48 lakh shares in the past one month. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 473.50% in the September 2025 quarter
Net profit of Venus Remedies rose 473.50% to Rs 20.13 crore in the quarter ended September 2025 as against Rs 3.51 crore during the previous quarter ended September 2024. Sales rose 13.32% to Rs 192.75 crore in the quarter ended September 2025 as against Rs 170.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales192.75170.10 13 OPM %16.064.45 - PBDT32.6615.48 111 PBT26.499.07 192 NP20.133.51 474 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Venus Remedies to convene board meeting
Venus Remedies will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 686.89% in the June 2025 quarter
Net profit of Venus Remedies rose 686.89% to Rs 9.60 crore in the quarter ended June 2025 as against Rs 1.22 crore during the previous quarter ended June 2024. Sales rose 21.44% to Rs 131.90 crore in the quarter ended June 2025 as against Rs 108.61 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales131.90108.61 21 OPM %7.6610.37 - PBDT18.7812.83 46 PBT12.606.85 84 NP9.601.22 687 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Venus Remedies to table results
Venus Remedies will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Venus Remedies to hold AGM
Venus Remedies announced that the 36th Annual General Meeting(AGM) of the company will be held on 22 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Venus Remedies to conduct board meeting
Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr
However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as against Rs 195.16 crore posted in the corresponding quarter of the previous year. Profit before tax surged 77.57% to Rs 31.04 crore in Q4 FY25, compared to Rs 17.48 crore in Q4 FY24. Total expenses slipped 6.01% YoY to Rs 170.69 crore in Q4 FY25. The cost of materials consumed was Rs 104.21 crore (up 23.80% YoY), while employee benefits expenses stood at Rs 21.16 crore (up 7.35% YoY) during the March 2025 quarter. During Q4 FY25, EBITDA stood at Rs 35.77 crore, up 52.92% from Rs 23.39 crore posted in the corresponding quarter last year. On a full-year basis, the company's consolidated net profit surged 59.07% to Rs 45.32 crore on a 7.72% jump in revenue from operations to Rs 647.89 crore in FY25 over FY24. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes. Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 99.81% in the March 2025 quarter
Net profit of Venus Remedies rose 99.81% to Rs 21.00 crore in the quarter ended March 2025 as against Rs 10.51 crore during the previous quarter ended March 2024. Sales declined 0.10% to Rs 194.97 crore in the quarter ended March 2025 as against Rs 195.16 crore during the previous quarter ended March 2024. For the full year,net profit rose 59.13% to Rs 45.32 crore in the year ended March 2025 as against Rs 28.48 crore during the previous year ended March 2024. Sales rose 7.72% to Rs 647.89 crore in the year ended March 2025 as against Rs 601.45 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales194.97195.16 0 647.89601.45 8 OPM %14.879.98 -9.819.91 - PBDT35.7523.37 53 84.4371.09 19 PBT31.0417.46 78 61.9244.64 39 NP21.0010.51 100 45.3228.48 59 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Venus Remedies to hold board meeting
Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.54%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.15% to 0.16%